| COVID-19 (severe/critical) |
Laboratory Findings |
Lymphocytes [1% increase vs. Not applicable] |
Odds ratio: 0.960 (0.930-0.990)
§ |
Tian
|
|
|
| COVID-19 (severe/critical) |
Laboratory Findings |
CRP [1 unit increase vs. Not applicable] |
Odds ratio: 1.010 (1.000-1.020)
§ |
Tian
|
|
|
| COVID-19 (severe/critical) |
Laboratory Findings |
Procalcitonin [1 unit increase vs. Not applicable] |
Odds ratio: 2.760 (1.250-3.930)
§ |
Tian
|
|
|
| COVID-19 (severe/critical) |
Laboratory Findings |
IL-2R [1 unit increase vs. Not applicable] |
Odds ratio: 1.000 (1.000-1.010)
§ |
Tian
|
|
|
| COVID-19 (severe/critical) |
Laboratory Findings |
IL-6 [1 unit increase vs. Not applicable] |
Odds ratio: 1.030 (1.000-1.050)
§ |
Tian
|
|
|
| COVID-19 (severe/critical) |
Laboratory Findings |
TNF alpha [1 unit increase vs. Not applicable] |
Odds ratio: 1.220 (1.010-1.470)
§ |
Tian
|
|
|
| COVID-19 (severe/critical) |
Treatment |
Antitumour treatment [Treated with Chemotherapy or Radiotherapy vs. Surgery] |
Odds ratio: 1.280 (0.850-1.940)
§ |
Tian
|
|
|
| COVID-19 (severe/critical) |
Patient characteristics |
Tumour stage [Stage IV (advanced tumour stage) vs. Stage I, II or III] |
Odds ratio: 2.600 (1.050-6.430)
§ |
Tian
|
|
|
| COVID-19 (severe/critical) |
Patient characteristics |
ECOG performance status [1 unit increase vs. Not applicable] |
Odds ratio: 2.800 (1.960-3.990)
§ |
Tian
|
|
|
| COVID-19 (severe/critical) |
Patient characteristics |
Age [1 year increase vs. Not applicable] |
Odds ratio: 1.040 (1.000-1.070)
§ |
Tian
|
|
|
| COVID-19 (severe/fatal) |
Treatment |
Concomitant medication [Treated with Anti-inflammatory drugs vs. Not received] |
Odds ratio: 2.930 (0.680-12.570)
§ |
Liabeuf
|
|
|
| COVID-19 (severe/fatal) |
Treatment |
Concomitant medication [Treated with renin-angiotensin system inhibitors (RASIs) vs. Not received] |
Odds ratio: 1.730 (1.020-2.930)
§ |
Liabeuf
|
|
|
| COVID-19 (severe/fatal) |
Treatment |
Concomitant medication [Treated with diuretics vs. Not received] |
Odds ratio: 1.350 (0.710-2.560)
§ |
Liabeuf
|
|
|
| COVID-19 (severe/fatal) |
Treatment |
Concomitant medication [Treated with beta-blockers vs. Not received] |
Odds ratio: 1.180 (0.640-2.190)
§ |
Liabeuf
|
|
|
| COVID-19 (severe/fatal) |
Comorbidities |
COPD [Present vs. Not present] |
Odds ratio: 1.600 (0.680-3.780)
§ |
Liabeuf
|
|
|
| COVID-19 (severe/fatal) |
Comorbidities |
Hypertension [Present vs. Not present] |
Odds ratio: 1.220 (0.630-1.730)
§ |
Liabeuf
|
|
|
| COVID-19 (severe/fatal) |
Comorbidities |
Coronary heart disease [Present vs. Not present] |
Odds ratio: 2.320 (1.040-5.190)
§ |
Liabeuf
|
|
|
| COVID-19 (severe/fatal) |
Patient characteristics |
Gender [Male vs. Female] |
Odds ratio: 1.540 (0.910-2.610)
§ |
Liabeuf
|
|
|
| COVID-19 (severe/fatal) |
Patient characteristics |
Age [1 year increase vs. Not applicable] |
Odds ratio: 1.010 (0.990-1.020)
§ |
Liabeuf
|
|
|
| Virus clearance |
Treatment |
Treatment for COVID-19 [Treated with convalescent plasma vs. Not received] |
Odds ratio: 10.310 (2.630-40.500)
|
Li
|
|
|
| COVID-19 (death) |
Treatment |
Treatment for COVID-19 [Treated with convalescent plasma vs. Not received] |
Odds ratio: 0.800 (0.370-1.720)
|
Li
|
|
|
| Hospital discharge |
Treatment |
Treatment for COVID-19 [Treated with convalescent plasma vs. Not received] |
Odds ratio: 1.670 (0.440-6.320)
|
Li
|
|
|
| COVID-19 (clinical improvement) |
Treatment |
Treatment for COVID-19 [Treated with convalescent plasma vs. Not received] |
Odds ratio: 0.860 (0.330-2.240)
|
Li
|
|
|
| COVID-19 (clinical improvement) |
Treatment |
Treatment for COVID-19 [Treated with convalescent plasma vs. Not received] |
Odds ratio: 0.880 (0.300-2.630)
|
Li
|
|
|
| Virus clearance |
Treatment |
Treatment for COVID-19 [Treated with convalescent plasma vs. Not received] |
Odds ratio: 13.570 (2.360-77.950)
|
Li
|
|
|
| Hospital discharge |
Treatment |
Treatment for COVID-19 [Treated with convalescent plasma vs. Not received] |
Odds ratio: 1.340 (0.980-1.830)
|
Li
|
|
|
| COVID-19 (clinical improvement) |
Treatment |
Treatment for COVID-19 [Treated with convalescent plasma vs. Not received] |
Hazard ratio: 1.340 (0.980-1.830)
|
Li
|
|
|
| COVID-19 (clinical improvement) |
Treatment |
Treatment for COVID-19 [Treated with convalescent plasma vs. Not received] |
Hazard ratio: 2.150 (1.070-4.320)
|
Li
|
|
|
| Virus clearance |
Treatment |
Treatment for COVID-19 [Treated with convalescent plasma vs. Not received] |
Odds ratio: 11.390 (3.910-33.180)
|
Li
|
|
|
| COVID-19 (death) |
Treatment |
Treatment for COVID-19 [Treated with convalescent plasma vs. Not received] |
Odds ratio: 0.650 (0.290-1.460)
|
Li
|
|
|
| Hospital discharge |
Treatment |
Treatment for COVID-19 [Treated with convalescent plasma vs. Not received] |
Odds ratio: 1.420 (0.900-2.240)
|
Li
|
|
|
| COVID-19 (clinical improvement) |
Treatment |
Treatment for COVID-19 [Treated with convalescent plasma vs. Not received] |
Odds ratio: 1.200 (0.800-1.810)
|
Li
|
|
|
| COVID-19 (clinical improvement) |
Treatment |
Treatment for COVID-19 [Treated with convalescent plasma vs. Not received] |
Odds ratio: 1.850 (0.910-3.770)
|
Li
|
|
|
| COVID-19 (clinical improvement) |
Treatment |
Treatment for COVID-19 [Treated with convalescent plasma vs. Not received] |
Odds ratio: 0.980 (0.300-3.190)
|
Li
|
|
|
| COVID-19 (clinical improvement) |
Treatment |
Treatment for COVID-19 [Treated with convalescent plasma vs. Not received] |
Hazard ratio: 1.400 (0.790-2.490)
|
Li
|
|
|
| COVID-19 (death) |
Treatment |
Concomitant medication [Treated with Palliative chemotherapy vs. No treatment] |
Odds ratio: 1.050 (0.630-1.760)
§ |
Lee
|
|
|
| COVID-19 (death) |
Treatment |
Concomitant medication [Treated with Palliative chemotherapy vs. Not received] |
Odds ratio: 1.480 (0.930-2.360)
§ |
Lee
|
|
|
| COVID-19 (death) |
Treatment |
Concomitant medication [Treated with Palliative first-line chemotherapy vs. Treated with Second-line (other line) chemotherapy] |
Odds ratio: 0.840 (0.360-1.980)
§ |
Lee
|
|
|
| COVID-19 (death) |
Treatment |
Concomitant medication [Treated with Non-palliative chemotherapy vs. Treated with Palliative chemotherapy] |
Odds ratio: 0.400 (0.170-0.960)
§ |
Lee
|
|
|
| COVID-19 (death) |
Treatment |
Concomitant medication [Treated with Targeted therapy vs. Not received] |
Odds ratio: 0.830 (0.450-1.540)
§ |
Lee
|
|
|
| COVID-19 (death) |
Treatment |
Concomitant medication [Treated with Radiotherapy vs. Not received] |
Odds ratio: 0.650 (0.360-1.180)
§ |
Lee
|
|
|
| COVID-19 (death) |
Treatment |
Concomitant medication [Treated with Immunotherapy vs. Not received] |
Odds ratio: 0.590 (0.270-1.270)
§ |
Lee
|
|
|
| COVID-19 (death) |
Treatment |
Concomitant medication [Treated with Hormone therapy vs. Not received] |
Odds ratio: 0.900 (0.490-1.680)
§ |
Lee
|
|
|
| COVID-19 (death) |
Treatment |
Concomitant medication [Treated with Chemotherapy vs. Not received] |
Odds ratio: 1.180 (0.810-1.720)
§ |
Lee
|
|
|
| COVID-19 (death) |
Patient characteristics |
BMI [Unknown vs. Normal (<25 kg/m2)] |
Hazard ratio: 1.970 (1.230-3.100)
§ |
Petrilli
|
|
|
| COVID-19 (death) |
Patient characteristics |
BMI [Severe obesity (>40kg/m2) vs. Normal (<25 kg/m2)] |
Hazard ratio: 1.450 (0.990-2.130)
§ |
Petrilli
|
|
|
| COVID-19 (death) |
Patient characteristics |
BMI [Obesity (30-39kg/m2) vs. Normal (<25 kg/m2)] |
Hazard ratio: 1.080 (0.870-1.360)
§ |
Petrilli
|
|
|
| COVID-19 (death) |
Patient characteristics |
BMI [Overweight (25-29kg/m2) vs. Normal (<25 kg/m2)] |
Hazard ratio: 1.010 (0.820-1.250)
§ |
Petrilli
|
|
|
| COVID-19 (death) |
Patient characteristics |
Smoking [Unknown vs. None] |
Hazard ratio: 1.500 (1.210-1.860)
§ |
Petrilli
|
|
|
| COVID-19 (death) |
Patient characteristics |
Smoking [Present vs. None] |
Hazard ratio: 0.920 (0.620-1.380)
§ |
Petrilli
|
|
|